Moolec Science (MLECW) Change in Intangibles (2023 - 2024)
Moolec Science (MLECW) posted Change in Intangibles of -$284372.0 for Q4 2024, down 29.36% sequentially from -$219829.0 in Q4 2023, and down 29.36% YoY from -$402568.2 in Q1 2024.
Moolec Science (MLECW) Change in Intangibles (2023 - 2024) Analysis & Trends
Moolec Science has reported Change in Intangibles for 2 years, with the latest figure at -$284372.0 in Q4 2024.
- Quarterly Change in Intangibles fell 29.36% year-over-year to -$284372.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$602159.0 (changed N/A YoY) and the FY2024 annual result came in at -$1.1 million, down 591.81% from the prior year.
- Change in Intangibles retreated to -$284372.0 in Q4 2024 per MLECW's latest filing, from -$219829.0 in the prior quarter.
- Over five years, Change in Intangibles peaked at -$18184.0 in Q2 2023 and troughed at -$284372.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.68 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -284,372.00 |
| Dec 31, 2024 | -284,372.00 |
| Dec 31, 2023 | -219,829.00 |
| Dec 31, 2023 | -219,829.00 |
| Jun 30, 2023 | -18,184.00 |
| Jun 30, 2023 | -18,184.00 |
| Mar 31, 2023 | -79,774.00 |
| Mar 31, 2023 | -79,774.00 |